Mark Y Chan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7367239/publications.pdf

Version: 2024-02-01

206 papers 5,210 citations

33 h-index 63 g-index

211 all docs

211 docs citations

times ranked

211

6522 citing authors

#	Article	IF	CITATIONS
1	Acute myocardial infarction and myocarditis following COVID-19 vaccination. QJM - Monthly Journal of the Association of Physicians, 2023, 116, 279-283.	0.5	42
2	Long-Term Clinical Outcomes of Biodegradable-Polymer Drug-Eluting Stents Versus Second-Generation Durable-Polymer Drug-Eluting Stents for ST-Segment Elevation Myocardial Infarction. Cardiovascular Revascularization Medicine, 2022, 35, 98-103.	0.8	0
3	Simultaneous cardio-cerebral infarction: a meta-analysis. QJM - Monthly Journal of the Association of Physicians, 2022, 115, 374-380.	0.5	12
4	One-year outcomes of patients with ST-segment elevation myocardial infarction during the COVID-19 pandemic. Journal of Thrombosis and Thrombolysis, 2022, 53, 335-345.	2.1	14
5	An Asian Perspective on Gender Differences in In-Hospital and Long-Term Outcome of Cardiac Mortality and Ischemic Stroke after Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106215.	1.6	3
6	Lipoprotein(a) as predictor of coronary artery disease and myocardial infarction in a multi-ethnic Asian population. Atherosclerosis, 2022, 349, 160-165.	0.8	11
7	Prevalence and outcomes of concomitant cardiac amyloidosis and aortic stenosis: A systematic review and meta-analysis. Hellenic Journal of Cardiology, 2022, 64, 67-76.	1.0	9
8	Variability of the Plasma Lipidome and Subclinical Coronary Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 100-112.	2.4	8
9	Sex differences in assessing stenosis severity between physician visual assessment and quantitative coronary angiography. International Journal of Cardiology, 2022, 348, 9-14.	1.7	5
10	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nature Reviews Cardiology, 2022, 19, 475-495.	13.7	180
11	Simultaneous Polar Metabolite and N-Glycan Extraction Workflow for Joint-Omics Analysis: A Synergistic Approach for Novel Insights into Diseases. Journal of Proteome Research, 2022, 21, 643-653.	3.7	3
12	Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: a systematic review and Bayesian network meta-analysis of randomized trials comprising of 43,875 patients. Journal of Thrombosis and Thrombolysis, 2022, 53, 671-682.	2.1	7
13	Myocardial infarction, stroke and cardiovascular mortality among migraine patients: a systematic review and meta-analysis. Journal of Neurology, 2022, 269, 2346-2358.	3.6	23
14	Effects of Sodium-Glucose Cotransporter 2 on Amputation Events: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials. Pharmacology, 2022, 107, 123-130.	2.2	9
15	A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study. European Heart Journal, 2022, 43, 1702-1711.	2.2	58
16	Cardiac remodelling–ÂPart 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 927-943.	7.1	29
17	Long-term Prognosis in Patients With Concomitant Acute Coronary Syndrome and Aortic Stenosis. Canadian Journal of Cardiology, 2022, 38, 1220-1227.	1.7	7
18	Clinical Characteristics and Long-Term Outcomes of Patients With Differing Haemoglobin Levels Undergoing Semi-Urgent and Elective Percutaneous Coronary Intervention in an Asian Population. Frontiers in Cardiovascular Medicine, 2022, 9, 687555.	2.4	1

#	Article	IF	Citations
19	Comparison of the Efficacy and Safety of Non-vitamin K Antagonist Oral Anticoagulants with Warfarin in Atrial Fibrillation Patients with a History of Bleeding: A Systematic Review and Meta-Analysis. American Journal of Cardiovascular Drugs, 2022, , 1.	2.2	2
20	Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials. American Journal of Cardiovascular Drugs, 2022, 299-323.	2.2	16
21	Prognostic Outcomes in Acute Myocardial Infarction Patients Without Standard Modifiable Risk Factors: A Multiethnic Study of 8,680 Asian Patients. Frontiers in Cardiovascular Medicine, 2022, 9, 869168.	2.4	24
22	Meta-Analysis of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Left Main Narrowing. American Journal of Cardiology, 2022, 173, 39-47.	1.6	7
23	SGLT inhibitors on weight and body mass: A metaâ€analysis of 116 randomizedâ€controlled trials. Obesity, 2022, 30, 117-128.	3.0	24
24	Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232210835.	2.5	19
25	Comparison of Mortality Outcomes in Acute Myocardial Infarction Patients With or Without Standard Modifiable Cardiovascular Risk Factors. Frontiers in Cardiovascular Medicine, 2022, 9, 876465.	2.4	12
26	A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	1.4	3
27	Long-Term Prognosis of Acute Myocardial Infarction Associated WithÂMetabolic Health and Obesity Status. Endocrine Practice, 2022, 28, 802-810.	2.1	12
28	Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiac Imaging Parameters: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of Cardiovascular Imaging, 2022, 30, 153.	0.7	5
29	Enhanced Thrombin Generation Is Associated with Worse Left Ventricular Scarring after ST-Segment Elevation Myocardial Infarction: A Cohort Study. Pharmaceuticals, 2022, 15, 718.	3.8	2
30	The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. Thrombosis and Haemostasis, 2021, 121, 422-432.	3.4	149
31	Association of Electrocardiographic P-Wave Markers and Atrial Fibrillation in Embolic Stroke of Undetermined Source. Cerebrovascular Diseases, 2021, 50, 46-53.	1.7	24
32	Characteristics and outcomes of young patients with ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: retrospective analysis in a multiethnic Asian population. Open Heart, 2021, 8, e001437.	2.3	12
33	Impact of the COVID-19 Pandemic on Door-to-Balloon Time for Primary Percutaneous Coronary Intervention ― Results From the Singapore Western STEMI Network ―. Circulation Journal, 2021, 85, 139-149.	1.6	50
34	Predicting mortality, thrombus recurrence and persistence in patients with post-acute myocardial infarction left ventricular thrombus. Journal of Thrombosis and Thrombolysis, 2021, 52, 654-661.	2.1	8
35	2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region. European Cardiology Review, 2021, 16, e02.	2.2	17
36	Association between smoking status and outcomes in myocardial infarction patients undergoing percutaneous coronary intervention. Scientific Reports, 2021, 11, 6466.	3.3	19

#	Article	IF	CITATIONS
37	Deletion of Mfsd2b impairs thrombotic functions of platelets. Nature Communications, 2021, 12, 2286.	12.8	18
38	A deep learning pipeline for automatic analysis of multi-scan cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 47.	3.3	13
39	Outcomes of left ventricular thrombosis in post-acute myocardial infarction patients stratified by antithrombotic strategies: A meta-analysis with meta-regression. International Journal of Cardiology, 2021, 329, 36-45.	1.7	13
40	Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients. Journal of Thrombosis and Thrombolysis, 2021, 52, 925-933.	2.1	5
41	Effects of Colchicine on Cardiovascular Outcomes in Patients with Coronary Artery Disease: A Systematic Review and One-Stage and Two-Stage Meta-Analysis of Randomized-Controlled Trials. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 343-354.	2.2	2
42	Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel. Cell Reports Medicine, 2021, 2, 100299.	6.5	2
43	The association of genetically determined serum glycine with cardiovascular risk in East Asians. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1840-1844.	2.6	4
44	Long-Term Outcomes of Stroke or Transient Ischemic Attack after Non-Emergency Percutaneous Coronary Intervention. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105786.	1.6	1
45	Remote Postdischarge Treatment of Patients With Acute Myocardial Infarction by Allied Health Care Practitioners vs Standard Care. JAMA Cardiology, 2021, 6, 830.	6.1	11
46	Anticoagulation for the treatment of left ventricular thrombus in patients with acute myocardial infarction and renal impairment. Polish Archives of Internal Medicine, 2021, 131, 878-881.	0.4	2
47	The Global Effect of the COVID-19 Pandemic on STEMI Care: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2021, 37, 1450-1459.	1.7	64
48	Association of Global Cardiac Calcification with Atrial Fibrillation and Recurrent Stroke in Patients with Embolic Stroke of Undetermined Source. Journal of the American Society of Echocardiography, 2021, 34, 1056-1066.	2.8	4
49	Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore. Pharmacogenomics Journal, 2021, 21, 243-250.	2.0	8
50	Low miRâ€19bâ€1â€5p Expression Is Related to Aspirin Resistance and Major Adverse Cardio―Cerebrovascular Events in Patients With Acute Coronary Syndrome. Journal of the American Heart Association, 2021, 10, e017120.	3.7	11
51	Tissue factor cytoplasmic domain exacerbates post-infarct left ventricular remodeling via orchestrating cardiac inflammation and angiogenesis. Theranostics, 2021, 11, 9243-9261.	10.0	13
52	The impact of chronic kidney disease on long-term outcomes following semi-urgent and elective percutaneous coronary intervention. Coronary Artery Disease, 2021, 32, 517-525.	0.7	2
53	Lipid profiles and outcomes of patients with prior cancer and subsequent myocardial infarction or stroke. Scientific Reports, 2021, 11, 21167.	3.3	5
54	Post-ST-Segment Elevation Myocardial Infarction Follow-Up Care During the COVID-19 Pandemic and the Possible Benefit of Telemedicine: An Observational Study. Frontiers in Cardiovascular Medicine, 2021, 8, 755822.	2.4	6

#	Article	IF	CITATIONS
55	Optimal glucose, HbA1c, glucose-HbA1c ratio and stress-hyperglycaemia ratio cut-off values for predicting 1-year mortality in diabetic and non-diabetic acute myocardial infarction patients. Cardiovascular Diabetology, 2021, 20, 211.	6.8	27
56	Diagnostic Performance of Fractional Flow Reserve From CT Coronary Angiography With Analytical Method. Frontiers in Cardiovascular Medicine, 2021, 8, 739633.	2.4	7
57	Tissue factor cytoplasmic domain exacerbates post-infarct left ventricular remodeling via orchestrating cardiac inflammation and angiogenesis. European Heart Journal, 2021, 42, .	2.2	0
58	Early Coronary Angiography Is Associated with Improved 30-Day Outcomes among Patients with out-of-Hospital Cardiac Arrest. Journal of Clinical Medicine, 2021, 10, 5191.	2.4	4
59	Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors. Nature Communications, 2021, 12, 6912.	12.8	6
60	Feasibility to Perform T ₂ * Mapping Postcontrast Administration in Reperfused STEMI Patients for the Detection of Intramyocardial Hemorrhage. Journal of Magnetic Resonance Imaging, 2020, 51, 644-645.	3.4	1
61	Screening and treatment of obstructive sleep apnea in acute coronary syndrome. A randomized clinical trial. International Journal of Cardiology, 2020, 299, 20-25.	1.7	4
62	Pneumococcal Pneumonia Resembling Acute Myocardial Infarction in an Adolescent Male. Pediatric Infectious Disease Journal, 2020, 39, 81-84.	2.0	1
63	Effect of Ticagrelor on Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction (HEALING-AMI). JACC: Cardiovascular Interventions, 2020, 13, 2220-2234.	2.9	17
64	Long-Term Outcomes and Recurrence of Left Ventricular Thrombus After Anticoagulation. Journal of the American College of Cardiology, 2020, 76, 484-486.	2.8	6
65	Detection of ADTRP in circulation and its role as a novel biomarker for coronary artery disease. PLoS ONE, 2020, 15, e0237074.	2.5	8
66	Interaction between a haptoglobin genetic variant and coronary artery disease (CAD) risk factors on CAD severity in Singaporean Chinese population. Molecular Genetics & Enomic Medicine, 2020, 8, e1450.	1.2	3
67	Coronavirus-induced myocarditis: A meta-summary of cases. Heart and Lung: Journal of Acute and Critical Care, 2020, 49, 681-685.	1.6	112
68	Prioritizing Candidates of Post–Myocardial Infarction Heart Failure Using Plasma Proteomics and Single-Cell Transcriptomics. Circulation, 2020, 142, 1408-1421.	1.6	50
69	Beta-blockers and renin-angiotensin system inhibitors in acute myocardial infarction managed with inhospital coronary revascularization. Scientific Reports, 2020, 10, 15184.	3.3	12
70	Cardiac and renal biomarkers in recreational runners following a 21 km treadmill run. Clinical Cardiology, 2020, 43, 1443-1449.	1.8	3
71	Impact of COVID-19 on health-related quality of life in patients with cardiovascular disease: a multi-ethnic Asian study. Health and Quality of Life Outcomes, 2020, 18, 387.	2.4	27
72	Effect of coronavirus infection on the human heart: A scoping review. European Journal of Preventive Cardiology, 2020, 27, 1136-1148.	1.8	21

#	Article	IF	CITATIONS
73	The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predict left ventricular thrombus resolution in acute myocardial infarction without percutaneous coronary intervention. Thrombosis Research, 2020, 194, 16-20.	1.7	11
74	Left Atrial Volume Index Predicts New-Onset Atrial Fibrillation and Stroke Recurrence in Patients with Embolic Stroke of Undetermined Source. Cerebrovascular Diseases, 2020, 49, 285-291.	1.7	32
75	Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation. Journal of Thrombosis and Thrombolysis, 2020, 50, 421-429.	2.1	3
76	Treating Very Long Coronary Artery Lesions in the Contemporary Drug-Eluting-Stent Era: Single Long 48 mm Stent Versus Two Overlapping Stents Showed Comparable Clinical Outcomes. Cardiovascular Revascularization Medicine, 2020, 21, 1115-1118.	0.8	10
77	Characterisation of patients with acute myocardial infarction complicated by left ventricular thrombus. European Journal of Internal Medicine, 2020, 74, 110-112.	2.2	7
78	Shared reference materials harmonize lipidomics across MS-based detection platforms and laboratories. Journal of Lipid Research, 2020, 61, 105-115.	4.2	55
79	LipidCreator workbench to probe the lipidomic landscape. Nature Communications, 2020, 11, 2057.	12.8	58
80	Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality. American Heart Journal, 2020, 224, 1-9.	2.7	3
81	Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements. Scientific Reports, 2020, 10, 6169.	3.3	14
82	The Lipid Paradox is present in ST-elevation but not in non-ST-elevation myocardial infarction patients: Insights from the Singapore Myocardial Infarction Registry. Scientific Reports, 2020, 10, 6799.	3.3	18
83	E/e' in relation to outcomes in STâ€elevation myocardial infarction. Echocardiography, 2020, 37, 554-560.	0.9	3
84	Building a Longitudinal National Integrated Cardiovascular Database ― Lessons Learnt From SingCLOUD ―. Circulation Reports, 2020, 2, 33-43.	1.0	7
85	Obesity in COVID-19: A Systematic Review and Meta-analysis. Annals of the Academy of Medicine, Singapore, 2020, 49, 996-1008.	0.4	57
86	A 78-year-old male with inferior ST-segment elevation on electrocardiogram, diabetic ketoacidosis and acute pancreatitis. Cardiovascular Endocrinology and Metabolism, 2020, 9, 186-188.	1.1	1
87	Nationalization of post-MI managed care: a worthy cause but not without its challenges. International Journal of Cardiology, 2019, 296, 28-29.	1.7	0
88	Independent Predictors of Cardiac Mortality and Hospitalization for Heart Failure in a Multi-Ethnic Asian ST-segment Elevation Myocardial Infarction Population Treated by Primary Percutaneous Coronary Intervention. Scientific Reports, 2019, 9, 10072.	3.3	15
89	Worry about Performance: Unravelling the Relationship between †Doing More' and †Doing Better'. Journal of Nutrition, Health and Aging, 2019, 23, 843-848.	3.3	1
90	Underlying Differences in the Treatment of Left Ventricular Thrombus With Non-Vitamin K Antagonist Oral Anticoagulants. American Journal of Cardiology, 2019, 124, 991-992.	1.6	1

#	Article	IF	Citations
91	Elevations in Serum Dickkopf-1 and Disease Progression in Community-Dwelling Older Adults With Mild Cognitive Impairment and Mild-to-Moderate Alzheimer's Disease. Frontiers in Aging Neuroscience, 2019, 11, 278.	3.4	11
92	Associations of osteopontin and NT-proBNP with circulating miRNA levels in acute coronary syndrome. Physiological Genomics, 2019, 51, 506-515.	2.3	4
93	Clinical Outcomes One Year and Beyond After Combination Sirolimus-Eluting Endothelial Progenitor Cell Capture Stenting During Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. Cardiovascular Revascularization Medicine, 2019, 20, 739-743.	0.8	0
94	Toll-like receptor 7 deficiency promotes survival and reduces adverse left ventricular remodelling after myocardial infarction. Cardiovascular Research, 2019, 115, 1791-1803.	3.8	25
95	Sex Differences in 1-Year Rehospitalization for Heart Failure and Myocardial Infarction After Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2019, 123, 1935-1940.	1.6	2
96	Characterisation of acute ischemic stroke in patients with left ventricular thrombi after myocardial infarction. Journal of Thrombosis and Thrombolysis, 2019, 48, 158-166.	2.1	26
97	P5719Plasma proteomics identify plaque-related proteins that predict long-term recurrent coronary events in patients with acute coronary syndrome. European Heart Journal, 2019, 40, .	2.2	0
98	P2582Signature of plasma extracellular vesicles associated proteins in acute myocardial infarction patients. European Heart Journal, 2019, 40, .	2.2	0
99	2348Novel direct thrombin inhibitor achieves superior antithrombotic effect with lower bleeding risk than heparin or bivalirudin. European Heart Journal, 2019, 40, .	2.2	0
100	Cardiac motion and spillover correction for quantitative PET imaging using dynamic MRI. Medical Physics, 2019, 46, 726-737.	3.0	5
101	Platelet inhibition to target reperfusion injury trial: Rationale and study design. Clinical Cardiology, 2019, 42, 5-12.	1.8	15
102	Air pollution in relation to very short-term risk of ST-segment elevation myocardial infarction: Case-crossover analysis of SWEDEHEART. International Journal of Cardiology, 2019, 275, 26-30.	1.7	16
103	Rationale and Design of the High Platelet Inhibition with Ticagrelor to Improve Left Ventricular Remodeling in Patients with ST-Segment Elevation Myocardial Infarction (HEALING-AMI) Trial. Korean Circulation Journal, 2019, 49, 586.	1.9	5
104	Prognostic Implications of Dual Platelet Reactivity Testing in Acute Coronary Syndrome. Thrombosis and Haemostasis, 2018, 118, 415-426.	3.4	5
105	Incidence and predictors of target lesion failure in a multiethnic Asian population receiving the SYNERGY coronary stent: A prospective allâ€comers registry. Catheterization and Cardiovascular Interventions, 2018, 92, 1097-1103.	1.7	14
106	Sources of variability in quantifying circulating thymosin beta-4: literature review and recommendations. Expert Opinion on Biological Therapy, 2018, 18, 141-147.	3.1	5
107	A propensity scoreâ€matched comparison of biodegradable polymer vs secondâ€generation durable polymer drugâ€eluting stents in a realâ€world population. Cardiovascular Therapeutics, 2018, 36, e12319.	2.5	2
108	Hybrid PET/CT and PET/MRI imaging of vulnerable coronary plaque and myocardial scar tissue in acute myocardial infarction. Journal of Nuclear Cardiology, 2018, 25, 2001-2011.	2.1	41

#	Article	IF	CITATIONS
109	Sleep Apnea Evolution and Left Ventricular Recovery After Percutaneous Coronary Intervention for Myocardial Infarction. Journal of Clinical Sleep Medicine, 2018, 14, 1773-1781.	2.6	11
110	Incidence and predictors of left ventricular thrombus by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: a meta-analysis. Journal of Cardiovascular Magnetic Resonance, 2018, 20, 72.	3.3	79
111	Surprisingly low incidence of left ventricular thrombosis in anterior STâ€segment elevation myocardial infarction. Clinical Cardiology, 2018, 41, 1297-1297.	1.8	1
112	First Medical Contact-to-Device Time and Heart Failure Outcomes Among Patients Undergoing Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004699.	2.2	12
113	Plasma Ceramides as Prognostic Biomarkers and Their Arterial and Myocardial Tissue Correlates in AcuteÂMyocardial Infarction. JACC Basic To Translational Science, 2018, 3, 163-175.	4.1	64
114	Costâ€effectiveness analysis of biodegradable polymer versus durable polymer drugâ€eluting stents incorporating realâ€world evidence. Cardiovascular Therapeutics, 2018, 36, e12442.	2.5	4
115	Impact of Cardioprotective Therapies on the Edema-Based Area at Risk by CMR in Reperfused STEMI. Journal of the American College of Cardiology, 2018, 71, 2856-2858.	2.8	9
116	Whole blood sequencing reveals circulating microRNA associations with high-risk traits in non-ST-segment elevation acute coronary syndrome. Atherosclerosis, 2017, 261, 19-25.	0.8	25
117	Integrated metabolomics and metallomics analyses in acute coronary syndrome patients. Metallomics, 2017, 9, 734-743.	2.4	16
118	Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non–ST-Segment Elevation Acute Coronary Syndrome. Clinical Chemistry, 2017, 63, 1214-1226.	3.2	9
119	Development of bioanalytical assays for variegin, a peptide-based bivalent direct thrombin inhibitor. Bioanalysis, 2017, 9, 693-705.	1.5	2
120	Avathrin: a novel thrombin inhibitor derived from a multicopy precursor in the salivary glands of the ixodid tick, <i>Amblyomma variegatum </i> . FASEB Journal, 2017, 31, 2981-2995.	0.5	14
121	Investigation of the novel androgen-dependent tissue factor pathway inhibitor regulating protein (ADTRP) and its role in coronary artery disease. Atherosclerosis, 2017, 263, e199-e200.	0.8	0
122	Genome-wide association study identifies a missense variant at APOA5 for coronary artery disease in Multi-Ethnic Cohorts from Southeast Asia. Scientific Reports, 2017, 7, 17921.	3.3	28
123	Effectiveness of advanced practice nurseâ€led telehealth on readmissions and healthâ€related outcomes among patients with postâ€acute myocardial infarction: <scp>ALTRA</scp> Study Protocol. Journal of Advanced Nursing, 2016, 72, 1357-1367.	3.3	13
124	Influence of Ethnicity, Age, and Time on Sex Disparities in Longâ€Term Causeâ€Specific Mortality After Acute Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	3.7	9
125	ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-Year results from a propensity score matched comparison. International Journal of Cardiology, 2016, 214, 483-484.	1.7	20
126	Obstructive Sleep Apnea and Cardiovascular Events After Percutaneous Coronary Intervention. Circulation, 2016, 133, 2008-2017.	1.6	178

#	Article	IF	Citations
127	Comparison of Long-Term Mortality of Patients Aged â‰ 4 0 Versus >40ÂYears With Acute Myocardial Infarction. American Journal of Cardiology, 2016, 118, 319-325.	1.6	8
128	The ethnicity-specific association of biomarkers with the angiographic severity of coronary artery disease. Netherlands Heart Journal, 2016, 24, 188-198.	0.8	10
129	Cost-Effectiveness Analysis of Ticagrelor and Prasugrel for the Treatment of Acute Coronary Syndrome. Value in Health Regional Issues, 2016, 9, 22-27.	1.2	11
130	Acute coronary syndrome in the Asia-Pacific region. International Journal of Cardiology, 2016, 202, 861-869.	1.7	85
131	Inter-Ethnic Differences in Quantified Coronary Artery Disease Severity and All-Cause Mortality among Dutch and Singaporean Percutaneous Coronary Intervention Patients. PLoS ONE, 2015, 10, e0131977.	2.5	13
132	Ethnicity Modifies Associations between Cardiovascular Risk Factors and Disease Severity in Parallel Dutch and Singapore Coronary Cohorts. PLoS ONE, 2015, 10, e0132278.	2.5	28
133	The diagnostic and prognostic potential of plasma extracellular vesicles for cardiovascular disease. Expert Review of Molecular Diagnostics, 2015, 15, 1577-1588.	3.1	46
134	Fasxiator, a novel factor XIa inhibitor from snake venom, and its siteâ€specific mutagenesis to improve potency and selectivity. Journal of Thrombosis and Haemostasis, 2015, 13, 248-261.	3.8	41
135	Long-Term Prognosis and Risk Heterogeneity of Heart Failure Complicating Acute Myocardial Infarction. American Journal of Cardiology, 2015, 115, 872-878.	1.6	19
136	Absorb Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent inÂST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity Score Matching Comparison. JACC: Cardiovascular Interventions, 2015, 8, 189-197.	2.9	145
137	Impact of the joint association between sex, age and diabetes on long-term mortality after acute myocardial infarction. BMC Public Health, 2015, 15, 308.	2.9	9
138	Biomarkers of Coronary Artery Disease Differ Between Asians and Caucasians in the General Population. Global Heart, 2015, 10, 301.	2.3	28
139	Circadian Dependence of Infarct Size and Acute Heart Failure in ST Elevation Myocardial Infarction. PLoS ONE, 2015, 10, e0128526.	2.5	34
140	High-grade culprit lesions are a common cause of STâ€'segment elevation myocardial infarction. Singapore Medical Journal, 2015, 56, 334-338.	0.6	1
141	Differences in late cardiovascular mortality following acute myocardial infarction in three major Asian ethnic groups. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 354-362.	1.0	19
142	Safety of combination therapy with milrinone and esmolol for heart protection during percutaneous coronary intervention in acute myocardial infarction. European Journal of Clinical Pharmacology, 2014, 70, 527-530.	1.9	5
143	Highly sensitive and quantitative human thrombospondin-1 detection by an M55 aptasensor and clinical validation in patients with atherosclerotic disease. Biosensors and Bioelectronics, 2014, 55, 405-411.	10.1	12
144	The Asia-Pacific Evaluation of Cardiovascular Therapies (ASPECT) Collaboration â€"Improving the quality of cardiovascular care in the Asia Pacific Region. International Journal of Cardiology, 2014, 172, 72-75.	1.7	13

#	Article	IF	Citations
145	Thought Leadership on Thrombotic Disorders in South East Asia. ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology, 2014, 22, 4.	0.0	0
146	Renal function and anaemia in acute myocardial infarction. International Journal of Cardiology, 2013, 168, 1397-1401.	1.7	8
147	Plasma extracellular vesicle protein content for diagnosis and prognosis of global cardiovascular disease. Netherlands Heart Journal, 2013, 21, 467-471.	0.8	22
148	Paradoxical effects of adiponectin level on plaque vulnerability and clinical outcomes after coronary revascularization. International Journal of Cardiology, 2013, 168, 4796-4798.	1.7	0
149	Anticoagulation and Monitoring of a Novel and Reversible Factor IXa Inhibitor. Drug Development Research, 2013, 74, 510-516.	2.9	1
150	Immigrant status and disparities in health care delivery in patients with myocardial infarction. International Journal of Cardiology, 2013, 166, 696-701.	1.7	5
151	Initial experience in the clinical use of everolimus-eluting bioresorbable vascular scaffold (BVS) in a single institution. International Journal of Cardiology, 2013, 168, 1536-1537.	1.7	9
152	Screening of hospitalized patients at high risk of obstructive sleep apnea in general cardiology service. International Journal of Cardiology, 2013, 164, 368-370.	1.7	5
153	Myocardial Infarction in Singapore: Ethnic Variation in Evidence-Based Therapy and Its Association with Socioeconomic Status, Social Network Size and Perceived Stress Level. Heart Lung and Circulation, 2013, 22, 1011-1017.	0.4	3
154	The influence of timing of polysomnography on diagnosis of obstructive sleep apnea in patients presenting with acute myocardial infarction and stable coronary artery disease. Sleep Medicine, 2013, 14, 985-990.	1.6	10
155	Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. International Journal of Cardiology, 2013, 167, 548-554.	1.7	10
156	Practice patterns, feasibility and efficacy of percutaneous coronary interventions (PCI) using small French size vascular access. International Journal of Cardiology, 2013, 168, 4287-4288.	1.7	2
157	A single-center experience of transitioning from a routine transfemoral to a transradial intervention approach in ST-elevation myocardial infarction: Impact on door-to-balloon time and clinical outcomes. Journal of Cardiology, 2013, 62, 12-17.	1.9	7
158	Relationship between apnoea-hypopnoea index and angiographic †coronary disease phenotypes in patients presenting with acute †myocardial infarction. Acute Cardiac Care, 2013, 15, 26-33.	0.2	6
159	Stent Embolization in the Current Era of Percutaneous Coronary Intervention: a NUHCS Experience. ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology, 2013, 21, .	0.0	0
160	Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). EuroIntervention, 2013, 9, 501-504.	3.2	52
161	Excessive Daytime Sleepiness is Associated with Longer Culprit Lesion and Adverse Outcomes in Patients with Coronary Artery Disease. Journal of Clinical Sleep Medicine, 2013, 09, 1267-1272.	2.6	19
162	P2Y12Platelet Receptors: Importance in Percutaneous Coronary Intervention. Arquivos Brasileiros De Cardiologia, 2013, 101, 277-82.	0.8	6

#	Article	IF	CITATIONS
163	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. New England Journal of Medicine, 2012, 367, 1297-1309.	27.0	765
164	Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization. JAMA - Journal of the American Medical Association, 2012, 308, 1785.	7.4	200
165	Translational platelet research in patients with coronary artery disease: What are the major knowledge gaps?. Thrombosis and Haemostasis, 2012, 108, 12-20.	3.4	9
166	Angiographic and platelet reactivity outcomes with prasugrel 60Âmg pretreatment and clopidogrel 60Âmg pretreatment in primary percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2012, 34, 499-505.	2.1	7
167	Adiponectin Profile in Asian Patients Undergoing Coronary Revascularization and Its Association With Plaque Vulnerability: IDEASâ€ADIPO Study. Obesity, 2012, 20, 2451-2457.	3.0	2
168	Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor. Thrombosis and Haemostasis, 2012, 108, 1180-1191.	3.4	33
169	Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban. Thrombosis, 2012, 2012, 1-10.	1.4	12
170	<i>CYP2C19</i> and <i>PON1</i> polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. Pharmacogenomics, 2012, 13, 533-542.	1.3	35
171	Clopidogrel pharmacogenetics of east, south and other Asian populations. European Heart Journal Supplements, 2012, 14, A41-A42.	0.1	15
172	Correlation between high density lipoprotein-cholesterol and remodeling index in patients with coronary artery disease: IDEAS (IVUS diagnostic evaluation of atherosclerosis in Singapore)-HDL study. International Journal of Cardiovascular Imaging, 2012, 28, 33-41.	1.5	18
173	Recalibration of the Global Registry of Acute Coronary Events risk score in a multiethnic Asian population. American Heart Journal, 2011, 162, 291-299.	2.7	27
174	Factor IXa as a Target for Pharmacologic Inhibition in Acute Coronary Syndrome. Cardiovascular Therapeutics, 2011, 29, e22-e35.	2.5	6
175	Severe Obstructive Sleep Apnea and Outcomes Following Myocardial Infarction. Journal of Clinical Sleep Medicine, 2011, 07, 616-621.	2.6	97
176	Clinical characteristics and prognostic importance of mild-to-moderate noninfarct-related coronary artery disease in patients with first ST-elevation myocardial infarction. Coronary Artery Disease, 2011, 22, 55-58.	0.7	0
177	Prevalence and predictors of premature discontinuation of dual antiplatelet therapy after drugâ€eluting stent implantation: importance of social factors in Asian patients. Internal Medicine Journal, 2011, 41, 623-629.	0.8	11
178	Utilisation of emergency medical service among Singapore patients presenting with ST-segment elevation myocardial infarction: prevalence and impact on ischaemic time. Internal Medicine Journal, 2011, 41, 809-814.	0.8	4
179	Effectiveness and Safety of the Genous Endothelial Progenitor Cell-Capture Stent in Acute ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2011, 108, 202-205.	1.6	20
180	Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial Design. Journal of Thrombosis and Thrombolysis, 2011, 32, 21-31.	2.1	23

#	Article	IF	Citations
181	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October $14\hat{a}\in^{a}16$, 2010, SÃ \pm o Paulo, Brazil. Journal of Thrombosis and Thrombolysis, 2011, 32, 242-266.	2.1	2
182	An Anti-von Willebrand Factor Aptamer Reduces Platelet Adhesion Among Patients Receiving Aspirin and Clopidogrel in an Ex Vivo Shear-Induced Arterial Thrombosis. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, E70-E78.	1.7	21
183	Effect on Bleeding, Time to Revascularization, and One-Year Clinical Outcomes of the Radial Approach During Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2010, 106, 148-154.	1.6	48
184	Procedure-Related Myonecrosis after Bare and Drug-Eluting Stent Implantation. Asian Cardiovascular and Thoracic Annals, 2010, 18, 272-278.	0.5	0
185	First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2010, 122, 614-622.	1.6	91
186	Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: A pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. American Heart Journal, 2010, 160, 1056-1064.e2.	2.7	19
187	Relation between combining evidence-based medications on mortality following myocardial infarction in patients with and without renal impairment. Acta Cardiologica, 2010, 65, 211-216.	0.9	0
188	Long-Term Mortality of Patients Undergoing Cardiac Catheterization for ST-Elevation and Non-ST-Elevation Myocardial Infarction. Circulation, 2009, 119, 3110-3117.	1.6	184
189	Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. Journal of Thrombosis and Thrombolysis, 2009, 28, 366-380.	2.1	24
190	Identification and treatment of arterial thrombophilia. Current Treatment Options in Cardiovascular Medicine, 2008, 10, 3-11.	0.9	4
191	Prevalence, Predictors, and Impact of Conservative Medical Management for Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Who Have Angiographically Documented Significant Coronary Disease. JACC: Cardiovascular Interventions, 2008, 1, 369-378.	2.9	48
192	A randomized, repeatâ€dose, pharmacodynamic and safety study of an antidoteâ€controlled factorÂlXa inhibitor. Journal of Thrombosis and Haemostasis, 2008, 6, 789-796.	3.8	97
193	Impact of Combination Evidence-Based Medical Therapy on Mortality Following Myocardial Infarction in Elderly Patients. The American Journal of Geriatric Cardiology, 2008, 17, 21-26.	0.6	10
194	Noninvasive, medical management for non–ST-elevation acute coronary syndromes. American Heart Journal, 2008, 155, 397-407.	2.7	20
195	Late-breaking trials summary from the 2008 American College of Cardiology Scientific Sessions, March 29 to April 1, Chicago, IL. American Heart Journal, 2008, 156, 7-12.	2.7	2
196	Prognostication of Valvular Aortic Stenosis Using Tissue Doppler Echocardiography: Underappreciated Importance of Late Diastolic Mitral Annular Velocity. Journal of the American Society of Echocardiography, 2008, 21, 475-481.	2.8	30
197	Prognostic value of left atrial size in chronic kidney disease. European Journal of Echocardiography, 2008, 9, 736-740.	2.3	18
198	Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease. Circulation, 2008, 117, 2865-2874.	1.6	125

#	Article	IF	CITATIONS
199	Hypercoagulable States in Cardiovascular Disease. Circulation, 2008, 118, 2286-2297.	1.6	110
200	Dilemma of drug-eluting stent implantation in a patient with systemic lupus erythematosus. International Journal of Cardiology, 2007, 114, E107-E108.	1.7	3
201	Sirolimus-eluting, bioabsorbable polymer-coated constant stent (Cura) in acute ST-elevation myocardial infarction: a clinical and angiographic study (CURAMI Registry). Journal of Invasive Cardiology, 2007, 19, 182-5.	0.4	17
202	Pretreatment with intracoronary adenosine reduces the incidence of myonecrosis after non-urgent percutaneous coronary intervention: a prospective randomized study. European Heart Journal, 2006, 28, 19-25.	2.2	47
203	Antecedent risk factors and their control in young patients with a first myocardial infarction. Singapore Medical Journal, 2006, 47, 27-30.	0.6	12
204	Reversible left ventricular apical ballooning after head injury. Clinical Cardiology, 2005, 28, 30-30.	1.8	6
205	Extrinsic compression of the left main coronary artery. European Heart Journal, 2005, 26, 2367-2367.	2.2	3
206	Fluvastatin: efficacy and safety in reducing cardiac events. Expert Opinion on Pharmacotherapy, 2005, 6, 1883-1895.	1.8	3